Establishment of Pancreatic Organoids from Normal Tissue and Tumors
- PMID: 33377086
- PMCID: PMC7757566
- DOI: 10.1016/j.xpro.2020.100192
Establishment of Pancreatic Organoids from Normal Tissue and Tumors
Abstract
Establishment of patient-derived adult stem cell-based pancreatic (tumor) organoids was first described in 2015. Since then, multiple laboratories have demonstrated the robustness of this method. We recently described the generation of a pancreatic cancer biobank containing 30 well-characterized tumor organoid models. Here, we describe the applied methods in detail. Use of tumor-selective media prevents contamination with normal cells. Generated organoids can be cryopreserved and can serve as a living biobank of pancreatic cancer for biomarker identification and drug screening. For complete information on the generation and use of this protocol, please refer to Driehuis et al. (2019).
Keywords: Cancer; Organoids; Stem Cells.
© 2020 The Author(s).
Conflict of interest statement
H.C. is a co-founder and SAB member of Surrozen, a start-up in Silicon Valley, and an SAB member of Merus (Utrecht), Volastra (New York), Decibel (Boston), DImed Inc. (Shanghai), Xilis Inc. (North Carolina). He is a non-executive board member of Roche (Basel) and a board/SAB member of the Roche subsidiary Genentech (San Francisco). He is a scientific advisor for and investor in Life Sciences Partners, a biotech venture capital firm located in Amsterdam. H.C. and S.F.B. are inventors on Organoid Technology patent applications relevant for this manuscript.
Figures








References
-
- Drost J., Clevers H. Organoids in cancer research. Nat. Rev. Cancer. 2018;18:407–418. - PubMed
-
- Drost J., van Jaarsveld R.H., Ponsioen B., Zimberlin C., van Boxtel R., Buijs A., Sachs N., Overmeer R.M., Offerhaus G.J., Begthel H. Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015;521:43–47. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources